 |
|
|
| |
Report 1.
International AIDS Conference (IAS)
in Rio de Janeiro, July 24-27, 2005
|
| |
| |
I thought you would like a preview of key oral ART presentations at IAS. The posters are not covered here but will include some interesting information as well.
Jules Levin
Late breakers
Comparative disease progression observed in newly diagnosed patients infected with drug resistant and susceptible HIV-1: no signs for increased virulence
Wensing A.M.J.1, van de Vijver D.A.M.C.2, Vercauteren J.3, Albert J.4, Bratt G.5, Clumeck N.6, Coughlan S.7, Grossman Z.8, Hatzakis A.9, Horban A.
1Department of Virology and Department of Internal Medicine, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Virology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rega Institute, Katho
TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMC114-C213)
Katlama C.1, Carvalho M.T.2, Cooper D.3, De Backer K.4, Lefebvre E.4, Pedro R.2, Rombouts K.4, Stoehr A.5, Vangeneugden T.4, Woehrmann A.6
1Hopital Pitie-Salpetriere, Paris, France, 2Hospital de Clinicas-UFPR, Curitiba, Brazil, 3University of New South Wales, Sydney, Australia, 4Tibotec BVBA, Mechelen, Belgium, 5IFI-Institut im AK St. Ge
Antiretroviral activity and tolerability of reverset (D-d4FC), a new fluoro-cytidine nucleoside analog when used in combination therapy in treatment-experienced patients: results of phase IIb study RVT-203
Cohen C.1, Katlama C.2, Murphy R.3, Gathe J.4, Brinson C.5, Richmond G.6, Girard P.-M.7, Fessel J.8, Liappis A.9, Puglia E.10, Rodwick B.<
1Community Research Initiative of New England, Boston, United States, 2Hopital de la Pitie Salpetriere, Paris, France, 3Northwestern University, Chicago, United States, 4Fannin St., Houston, United States,
Antiretroviral treatment strategies
Oral Abstract Sessions
Investigating cellular antiretroviral resistance: preliminary results of the ICARE study
Lafeuillade A.1, Hittinger G.1, Poggi C.2, Benech H.3, Cupo A.4
1CHITS, Toulon, France, 2General Hospital, Toulon, France, 3CEA, Gif sur Yvette, France, 4CNRS, Sofia Antipolis, France
Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients
Pozniak A.L.1, Gallant J.E.2, DeJesus E.3, Campo R.4, Arribas J.R.5, Gazzard B.1, Lu B.6, McColl D.6, Enejosa J.6, Cheng A.K.6
1Chelsea and Westminster Hospital, London, United Kingdom, 2Johns Hopkins University School of Medicine, Baltimore, United States of America, 3Orlando Immunology Center, Orlando, United States of America, 4University of Miami, Miami, United States of America, 5University Hospital La Paz, Madrid, Spain, 6Gilead Sciences, Foster City, United States of America
The level of persistent viremia does not increase after simplification of maintenance antiretroviral therapy to lopinavir/ritonavir alone.
McKinnon J.E.1, Arribas J.R.2, Pulido F.3, Delgado R.3, Mellors J.W.1
1University of Pittsburgh, Pittsburgh, United States of America, 2Hospital La Paz, Madrid, Spain, 3Hospital Doce de Octubre, Madrid, Spain
Viral suppression in CSF and genital tract in ritonavir-boosted "atazanavir only" maintenance therapy (ATARITMO-Study)
Vernazza P.1, Daneel S.1, Schiffer V.2, Decosterd L.3, Hirschel B.2, and the Swiss HIV Cohort S.1
1Cantonal Hospital, St. Gallen, Switzerland, 2University Hospital Geneva, Geneva, Switzerland, 3CHUV, Lausanne, Switzerland
Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400 copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced HIV+ patients.
Valdez H.1, McCallister S.1, Kohlbrenner V.1, Mayers D.1
1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, United States of America
Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ritonavir tablet formulation
Awni W.1, Chiu Y.-L.1, Zhu T.1, Braun N.1, Klein C.1, Heuser R.1, Breitenbach J.1, Morris J.1, Doan T.1, Brun S.1, Hanna G.1
1Abbott Laboratories, Abbott Park, IL, United States of America
New antiretroviral agents
Small molecule HIV entry inhibitors targeting gp41 (fusion)
Jiang S.1, Lu H.1, Liu S.1, Zhao Q.1, He Y.1, Debnath A.K.1
1New York Blood Center, New York, United States of America
Immune therapy of advanced HIV-1 infection by transduced autologous T helper cells expressing a peptide which inhibits viral entry. Results of a phase I pilot study.
van Lunzen J.1, Glaunsinger T.1, Stahmer I.1, KÃ_hlcke K.2, Schilz A.2, Stellbrink H.J.1, Mayr C.3, Dinauer N.4, Alexandrov A.4, von Laer D.5
1University Medical Center Eppendorf, Hamburg, Germany, 2EUFETS AG, Idar-Oberstein, Germany, 3Private Practice Seestrasse, Berlin, Germany, 4Fresenius Biotech AG, Bad Homburg, Germany, 5Georg-Speyer-Haus, Frankfurt, Germany
Treatment with growth hormone leads to improvement in total and naive CD4 lymphocyte recovery in HIV-infected subjects with incomplete immune reconstitution on HAART
Smith K.1, Wang R.2, Bosch R.2, Margolis D.3, Tenorio A.1, Pollard R.4, Stocker V.5, Gross B.6, Frances I.6, Muurahainen N.7, ACTG 5174 Protocol Team A.5
1Rush University Medical Center, Chicago, United States of America, 2Harvard School of Public Health, Boston, United States of America, 3UT Southwestern Medical Center, Dallas, United States of America, 4UC Davis Medical Center, San Diego, United States of America, 5AACTG Operations Center, Silver Spring, United States of America, 6University of Michigan, Ann Arbor, United States of America, 7Serono, Inc, Rockland, United States of America
Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857)
McHale M.1, Abel S.1, Russell D.1, Gallagher J.1, van der Ryst E.1
1Pfizer Global Research and Development, Sandwich, United Kingdom
SCH 417690: antiviral activity of a potent new CCR5 receptor antagonist
Schuermann D.1, Pechardscheck C.1, Rouzier R.2, Nougarede R.2, Faetkenheuer G.3, Ochlast I.3, Raffi F.4, Hoffman C.5, Greaves W.6, Sansone A.6
1Charatie Hospital, Berlin, Germany, 2CentreCap, Montpellier, France, 3University of Cologne, Cologne, Germany, 4Biotrial/University Hospital, Nantes and Rennes, France, 5University of Kiel, Kiel, Germany, 6Schering Plough Research Institute, Kenilworth, New Jersey, United States of America
Antiviral synergy between the CCR5 mAb PRO 140 and small-molecule CCR5 antagonists
Murga J.1, Olson W.1, Pevear D.1
1Progenics Pharmaceuticals, Inc., Tarrytown, United States of America
|
|
| |
|
|
|
|
|
